Loop diuretics represent a double-edged therapeutic reality in heart failure management. While essential for reducing pulmonary and peripheral congestion, these agents simultaneously accelerate urinary thiamine losses, creating measurable deficiency in approximately one-third of hospitalized patients. The first clinical imperative is recognizing this mechanism: diuretic-driven depletion is not incidental—it is systemic and predictable.
Second, the metabolic stakes are high. Pyruvate dehydrogenase, dependent entirely on thiamine cofactor availability, controls the primary ATP production pathway within cardiomyocytes. Deficiency forces an inefficient metabolic shift toward lactate production and energy deficit—directly opposing therapeutic goals in heart failure management.
Third, intervention is straightforward. Thiamine screening is simple and inexpensive, supplementation carries minimal risk, and evidence supports correcting documented deficiency. Yet current practice largely overlooks this gap. Integrating thiamine assessment into heart failure protocols represents a low-cost, evidence-aligned opportunity to optimize cardiac energy metabolism.
Was this article helpful?
